Biogen Says New Data Shows Promise For Potential New Generation Of Treatments In Early Alzheimer's Disease
Portfolio Pulse from Nabaparna Bhattacharya
Biogen Inc. has reported new Phase 1b clinical data from the study of BIIB080, a therapy targeting tau in mild Alzheimer's disease. The data showed favorable trends on multiple exploratory endpoints of cognition and activities of daily living. The results were presented at the 2023 Clinical Trials on Alzheimer's Disease meeting. Biogen is currently recruiting for the Phase 2 CELIA study, evaluating the potential for this therapy to slow the worsening of mild cognitive impairment or mild dementia due to Alzheimer's disease. BIIB shares are trading lower by 2.26% to $246.41.

October 25, 2023 | 4:20 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Biogen's new Phase 1b clinical data for BIIB080 shows promise in treating mild Alzheimer's disease. Despite the positive news, BIIB shares are trading lower.
The promising clinical data for BIIB080 indicates potential future success for Biogen in the Alzheimer's treatment market. However, despite this positive news, the company's shares are trading lower, indicating that the market may not have fully absorbed or reacted to this news yet.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100